Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
about
Relevance of tumor-infiltrating lymphocytes in breast cancerCombination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionControl of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cellsThe availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patientsTumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapyCostimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic GlycolysisEnhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?Melanoma vaccines: developments over the past 10 years.T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors.A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
P2860
Q26795598-96BBACF3-C43E-4E2D-8508-440FC02D9B90Q28740530-40CEFB5A-D178-4FE1-9298-7F85E7E5D903Q30430481-C9315DDE-2B1A-47E1-8DE2-6A816F9C15C4Q34778826-A95C1773-2AFB-443C-B629-722373E241DAQ35228053-9263C5DF-3035-4F08-ADAF-CF2C436F9544Q36057487-A30A9D96-5548-49BA-9EF6-8DE0C9651794Q36349514-5B5C82D7-444A-44D1-8537-8BE04D1A097AQ36387235-42AC7973-6D5E-4621-9A79-661BB42B2440Q37114367-C062E1EE-8607-4F4A-A57C-D9A8B0FEFF86Q37773303-E91FA005-BDA9-4909-B343-054B1371F347Q37892595-F8CC7DB1-9491-4E65-9B8A-FF010D187A9FQ37948129-87A6BA30-7700-4B1F-B083-58EA7A34BA1DQ38088635-38E9BB74-7B74-4C1F-B825-BFDE070E928CQ38108836-979DC800-005B-4292-BFD7-746B01D74433Q38374889-866658A9-A4A7-4D9F-8F8C-2FB98A794D9DQ38770814-8E511457-85D2-427B-A9B8-2256CFA1A251Q38779877-4B1F82BC-43EE-46C9-A517-C345829D2654Q43248975-E9FCAA21-0E1E-4F97-9181-8D10302D22D4Q47275317-D3011C16-FE1F-4321-8AAB-ED7990E10914Q47325439-ACDC2ABD-9B65-4533-9A91-BB4670AE746CQ48256829-581A7937-40C5-4884-8FAE-E2BAC020642A
P2860
Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Optimising anti-tumour CD8 T-c ...... f immunomodulatory antibodies.
@en
Optimising anti-tumour CD8 T-c ...... f immunomodulatory antibodies.
@nl
type
label
Optimising anti-tumour CD8 T-c ...... f immunomodulatory antibodies.
@en
Optimising anti-tumour CD8 T-c ...... f immunomodulatory antibodies.
@nl
prefLabel
Optimising anti-tumour CD8 T-c ...... f immunomodulatory antibodies.
@en
Optimising anti-tumour CD8 T-c ...... f immunomodulatory antibodies.
@nl
P2093
P2860
P356
P1476
Optimising anti-tumour CD8 T-c ...... of immunomodulatory antibodies
@en
P2093
Aymen Al-Shamkhani
Juliet C Gray
Martin J Glennie
Ruth R French
Sonya James
P2860
P304
P356
10.1002/EJI.200838208
P407
P577
2008-09-01T00:00:00Z